Nomination Committee for the AGM 2023
According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB, resolved at the annual general meeting on May 11, 2022, the nomination committee shall, besides the Chair of the Board, consist of representatives of the three largest shareholders, or groups of shareholders, registered by Euroclear Sweden AB as per August 31, 2022.
The three largest shareholders or groups of shareholders have now appointed their representatives, thus the nomination committee ahead of the AGM 2023 comprises the following members:
- Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of IRLAB’s founders. Appointed by a group of shareholders that consists of the company’s founders representing slightly less than 14 per cent of shares and votes;
- Hans-Peter Ostler, background from bank and investment advisory, appointed by a group of shareholders representing slightly more than 13 per cent of shares and votes;
- Anders Vedin, background from executive positions in global pharmaceutical companies, appointed by a group of shareholders representing slightly more than 13 per cent of shares and votes; and
- Carola Lemne, Chair of the Board of IRLAB Therapeutics AB.
The members of the nomination committee have been appointed by owners who represent a total of about 40 per cent of the total number of shares and votes in IRLAB Therapeutics AB as per May 30, 2023.
The nomination committee’s proposals were presented in the summon to the annual general meeting 2023 and on the company’s web page: www.irlab.se.
Shareholders who wished to submit proposals to the nomination committee should have done this in writing, no later than January 31, 2023, via e-mail email@example.com or via mail to the company’s postal address.